News
MNOV
1.810
+2.26%
0.040
Weekly Report: what happened at MNOV last week (1007-1011)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 4d ago
Weekly Report: what happened at MNOV last week (0930-1004)?
Weekly Report · 10/07 10:41
MediciNova Announces That The National Institutes Of Health Neurological Disorders And Stroke Has Awarded $22M For An Intermediate Size Expanded Access Protocol To Evaluate The Efficacy Of MN-166 In Amyotrophic Lateral Sclerosis
Benzinga · 09/30 13:05
MediciNova to support NIH-funded EAP trial to evaluate MN166 in ALS
TipRanks · 09/30 13:05
MEDICINOVA INC - NIH AWARDS $22 MILLION FOR EAP TO EVALUATE MN-166 IN ALS
Reuters · 09/30 13:00
Weekly Report: what happened at MNOV last week (0923-0927)?
Weekly Report · 09/30 10:36
Weekly Report: what happened at MNOV last week (0916-0920)?
Weekly Report · 09/23 10:36
Weekly Report: what happened at MNOV last week (0909-0913)?
Weekly Report · 09/16 10:29
MEDICINOVA ANNOUNCES ABSTRACT REGARDING MN-166 (IBUDILAST) IN COMBAT-ALS CLINICAL TRIAL ACCEPTED FOR POSTER PRESENTATION AT THE 35TH INTERNATIONAL SYMPOSIUM ON ALS / MND
Reuters · 09/09 23:00
Weekly Report: what happened at MNOV last week (0902-0906)?
Weekly Report · 09/09 10:36
MEDICINOVA ANNOUNCES ACCEPTANCE OF ABSTRACT REGARDING MN-166 (IBUDILAST) IN COMBAT-ALS CLINICAL TRIAL FOR PRESENTATION AT THE 2024 ANNUAL NEALS (NORTHEAST AMYOTROPHIC LATERAL SCLEROSIS CONSORTIUM) MEETING
Reuters · 09/03 23:00
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 09/03 17:41
Weekly Report: what happened at MNOV last week (0826-0830)?
Weekly Report · 09/02 10:39
Sector Update: Health Care Stocks Rise Late Afternoon
NASDAQ · 08/30 19:55
Sector Update: Health Care Stocks Softer in Afternoon Trading
NASDAQ · 08/30 17:53
MediciNova gains after patent win for long COVID therapy
Seeking Alpha · 08/30 12:11
Reported Earlier, MediciNova Receives U.S. Patent Allowance For MN-166, Ensuring Broad Protection For Post-COVID Treatment Through 2042
Benzinga · 08/30 07:53
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
Barchart · 08/29 18:00
Weekly Report: what happened at MNOV last week (0819-0823)?
Weekly Report · 08/26 10:37
More
Webull provides a variety of real-time MNOV stock news. You can receive the latest news about Medicinova through multiple platforms. This information may help you make smarter investment decisions.
About MNOV
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.